BlackRock, Inc. Amends Schedule 13G/A for Stoke Therapeutics, Inc.

BlackRock, Inc. has filed an amendment to its Schedule 13G/A for Stoke Therapeutics, Inc., reporting ownership of 3,732,540 shares, which represents 6.8% of the company's common stock. The filing indicates that BlackRock has sole voting power over 3,666,122 shares and sole dispositive power over all 3,732,540 shares. The amendment reflects changes in ownership, with a decrease of 2,192,027 shares compared to the previous filing, representing a 36.9989% reduction. The value of the holdings has increased by 86.1168% to $125,152,066.20. The filing also notes that various persons have the right to receive dividends or proceeds from the sale of the shares, but no single person's interest exceeds 5% of the total outstanding shares. The amendment was signed by Spencer Fleming, Managing Director of BlackRock, Inc.